Abstract
Over the past decades, the paradigm that lysosomal enzymes participate only in non-specific protein degradation during cell death has changed. Studies conducted both in cell cultures and in animals defined the role of these enzymes that includes cathepsin D (CD). Knockout mice revealed the role of CD in postnatal tissue homeostasis and remodeling. Mutations that abolish the CD enzymatic activity have been implicated in neural ceroid lipofuscinosis. Recent studies suggested a differential role of CD in regulation of apoptosis. The zymogen of CD, procathepsin D (pCD), is secreted by various cancer cells. Extensive studies showed that it acts as a mitogen on both cancer and stromal cells by stimulating their invasive and metastatic properties. Additional studies suggested that procathepsin D/CD is an independent prognostic factor in various cancers, leading to the investigations of pCD/CD as a potential target for designing anti-cancer therapy. In this review, we described the various forms of CD and their implications in numerous physiological as well as pathological conditions.
Keywords: Alzheimer's disease, apoptosis, cancer, cathepsin D, knockout mice, procathepsin D
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Pleiotropic Effects of Cathepsin D
Volume: 9 Issue: 4
Author(s): Aruna Vashishta, Sujata Saraswat Ohri and Vaclav Vetvicka
Affiliation:
Keywords: Alzheimer's disease, apoptosis, cancer, cathepsin D, knockout mice, procathepsin D
Abstract: Over the past decades, the paradigm that lysosomal enzymes participate only in non-specific protein degradation during cell death has changed. Studies conducted both in cell cultures and in animals defined the role of these enzymes that includes cathepsin D (CD). Knockout mice revealed the role of CD in postnatal tissue homeostasis and remodeling. Mutations that abolish the CD enzymatic activity have been implicated in neural ceroid lipofuscinosis. Recent studies suggested a differential role of CD in regulation of apoptosis. The zymogen of CD, procathepsin D (pCD), is secreted by various cancer cells. Extensive studies showed that it acts as a mitogen on both cancer and stromal cells by stimulating their invasive and metastatic properties. Additional studies suggested that procathepsin D/CD is an independent prognostic factor in various cancers, leading to the investigations of pCD/CD as a potential target for designing anti-cancer therapy. In this review, we described the various forms of CD and their implications in numerous physiological as well as pathological conditions.
Export Options
About this article
Cite this article as:
Vashishta Aruna, Ohri Saraswat Sujata and Vetvicka Vaclav, Pleiotropic Effects of Cathepsin D, Endocrine, Metabolic & Immune Disorders - Drug Targets 2009; 9 (4) . https://dx.doi.org/10.2174/187153009789839174
DOI https://dx.doi.org/10.2174/187153009789839174 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Melatonin and Synthetic Melatoninergic Agonists in Psychiatric and Age-associated Disorders: Successful and Unsuccessful Approaches
Current Pharmaceutical Design Voltage-Gated Sodium Channel Blockers as Immunomodulators
Recent Patents on CNS Drug Discovery (Discontinued) Status Epilepticus in the Immature Rodent Brain Alters the Dynamics of Autophagy
Current Neurovascular Research The Urokinase Receptor Interactome
Current Pharmaceutical Design Functional Multipotency of Stem Cells: A Conceptual Review of Neurotrophic Factor-Based Evidence and Its Role in Translational Research
Current Neuropharmacology CETUXIMAB: From Bench to Bedside
Current Cancer Drug Targets Role of Progastrins and Gastrins and Their Receptors in GI and Pancreatic Cancers: Targets for Treatment
Current Pharmaceutical Design Metallodrugs in Targeted Cancer Therapeutics: Aiming at Chemoresistance- related Patterns and Immunosuppressive Tumor Networks
Current Medicinal Chemistry Cancer Chemoprevention by Targeting the Epigenome
Current Drug Targets Protein Kinase C Isoforms - Implications to Thrombosis
Current Signal Transduction Therapy Selenium Compounds and Apoptotic Modulation: A New Perspective in Cancer Therapy
Mini-Reviews in Medicinal Chemistry New Technologies for Drug Delivery Across the Blood Brain Barrier
Current Pharmaceutical Design Recent Innovations in Antibody-Mediated, Targeted Particulate Nanotechnology and Implications for Advanced Visualisation and Drug Delivery
Current Nanoscience Antisense Strategies in Therapy of Gliomas
Current Signal Transduction Therapy Radiation and Gene Therapy: Rays of Hope for the New Millennium?
Current Gene Therapy Recent Developments in Chimeric NSAIDs as Anticancer Agents: Teaching an Old Dog a New Trick
Mini-Reviews in Medicinal Chemistry Subject Index to Volume 4
Current Pharmaceutical Biotechnology Host Pharmacogenetics in the Treatment of HIV and Cancer
Current Drug Safety Utilizing Ultrasound to Transiently Increase Blood-Brain Barrier Permeability, Modulate of the Tight Junction Proteins, and Alter Cytoskeletal Structure
Current Neurovascular Research DNA Demethylation: Where Genetics Meets Epigenetics
Current Pharmaceutical Design